Lupin gets USFDA’s nod for Clobazam Oral Suspension

31 Dec 2018 Evaluate

Lupin has received approval for its Clobazam Oral Suspension, 2.5 mg/mL from the United States Food and Drug Administration (USFDA) to market a generic version of Lundbeck Pharmaceuticals LLC's Onfi Oral Suspension, 2.5 mg/ml. Clobazam Oral Suspension, 2.5 mg/mL had annual sales of approximately $260.2 million in the US (IQVIA MAT September 2018).

Lupin's Clobazam Oral Suspension, 2.5 mg/mL is the generic version of Lundbeck Pharmaceuticals, LLC's Onfi Oral Suspension, 2.5 mg/ml. It is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients 2 years of age or older.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2113.40 -25.25 (-1.18%)
02-Feb-2026 09:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1613.85
Dr. Reddys Lab 1190.50
Cipla 1309.40
Zydus Lifesciences 875.45
Lupin 2113.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×